Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neurocutaneous Syndromes”

448 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 448 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03190915
What this trial is testing

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Who this might be right for
Juvenile Myelomonocytic LeukemiaNeurofibromatosis Type 1
National Cancer Institute (NCI) 10
Not applicableStudy completedNCT05471310
What this trial is testing

Videoocular Assessment of Eye Movement Activity in an Ataxia Telangiectasia

Who this might be right for
Ataxia TelangiectasiaDysmetria
Federal Research Institute of Pediatric Hematology, Oncology and Immunology 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT02407405
What this trial is testing

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Who this might be right for
Neurofibromatosis 1 (NF1)Plexiform Neurofibromas (PN)
National Cancer Institute (NCI) 36
Not applicableActive Not RecruitingNCT04759781
What this trial is testing

MElanoma Research Lymph Node Prediction Implementation National_001

Who this might be right for
Melanoma
SkylineDx 1,820
Not applicableStudy completedNCT04991428
What this trial is testing

Mechanism of Action of Transcranial Direct Current Stimulation in Neurofibromatosis Type 1

Who this might be right for
Neurofibromatosis 1
University of Manchester 31
Early research (Phase 1)Study completedNCT01031901
What this trial is testing

Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)

Who this might be right for
Tuberous SclerosisNeurofibromatosesAngiofibroma+1 more
The University of Texas Health Science Center, Houston 52
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05253131
What this trial is testing

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

Who this might be right for
MPNSTNF1Sarcoma
University of Alabama at Birmingham 41
Not applicableStudy completedNCT02246231
What this trial is testing

Effect of Implant Position on Magnetic Resonance Image Distortion

Who this might be right for
Neurofibromatosis Type 2
Manchester University NHS Foundation Trust 5
Not applicableUnknownNCT03757247
What this trial is testing

Prevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 Mutation

Who this might be right for
Neurofibromatosis Type 1
Medical University Innsbruck 670
Early research (Phase 1)Active Not RecruitingNCT04895748
What this trial is testing

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Who this might be right for
Carcinoma, Renal Cell
Novartis Pharmaceuticals 40
Large-scale testing (Phase 3)Active Not RecruitingNCT02962414
What this trial is testing

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Who this might be right for
Tuberous Sclerosis Complex
Novartis Pharmaceuticals 206
Testing effectiveness (Phase 2)Looking for participantsNCT07371663
What this trial is testing

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

Who this might be right for
Solid CancersNSCLC (Advanced Non-small Cell Lung Cancer)Gastric (Stomach) Cancer+2 more
Beijing Tide Pharmaceutical Co., Ltd 266
Early research (Phase 1)Not Yet RecruitingNCT06934928
What this trial is testing

Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs)

Who this might be right for
Neurofibromatosis 1 (NF1)Neurofibromatosis Type I
Massachusetts General Hospital 10
Not applicableLooking for participantsNCT06379230
What this trial is testing

A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE)

Who this might be right for
Neurofibromatosis 1Plexiform Neurofibroma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University 2,000
Testing effectiveness (Phase 2)Ended earlyNCT01345136
What this trial is testing

Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

Who this might be right for
Neurofibromatosis Type 2Neuroma, Acoustic
Jonsson Comprehensive Cancer Center 4
Not applicableLooking for participantsNCT05424016
What this trial is testing

Propranolol and Von Hippel-Lindau Disease

Who this might be right for
Hemangioblastoma of CNSVon Hippel-Lindau Disease
Assistance Publique - Hôpitaux de Paris 85
Not applicableLooking for participantsNCT00598351
What this trial is testing

Natural History Study of Patients With Neurofibromatosis Type 2

Who this might be right for
Neurofibromatosis
National Institute of Neurological Disorders and Stroke (NINDS) 269
Not applicableStudy completedNCT00970970
What this trial is testing

Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease

Who this might be right for
Von Hippel-Lindau DiseaseHemangioblastomaRenal Cell Carcinoma+2 more
University Medical Center Groningen 22
Testing effectiveness (Phase 2)WithdrawnNCT05825365
What this trial is testing

Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study

Who this might be right for
Neurofibromatosis Type 1Plexiform NeurofibromasPost-operative
AstraZeneca
Testing effectiveness (Phase 2)Study completedNCT03433183
What this trial is testing

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Who this might be right for
Malignant Peripheral Nerve Sheath TumorsNeurofibromatosis 1
Sarcoma Alliance for Research through Collaboration 21
Load More Results